Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Filanesib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Filanesib: Sponsors, patents, clinical trial progress

Filanesib is an investigational drug.

There have been 4 clinical trials for Filanesib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and [disabled in preview]. The leading clinical trial sponsors are Array BioPharma, PETHEMA Foundation, and Celgene Corporation.

There are fifteen US patents protecting this investigational drug and one hundred and thirteen international patents.

Recent Clinical Trials for Filanesib
Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseAdknoma Health ResearchPhase 2
Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseMerck Sharp & Dohme Corp.Phase 2
Pembrolizumab (MK-3475) in MM Patients With Residual DiseasePETHEMA FoundationPhase 2

See all Filanesib clinical trials

Clinical Trial Summary for Filanesib

Top disease conditions for Filanesib
Top clinical trial sponsors for Filanesib

See all Filanesib clinical trials

US Patents for Filanesib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Filanesib   Start Trial Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)   Start Trial
Filanesib   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
Filanesib   Start Trial Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.